Breaking News Instant updates and real-time market news.

NBIX

Neurocrine

$115.86

-0.32 (-0.28%)

08:00
08/07/18
08/07
08:00
08/07/18
08:00

Neurocrine initiated with a Buy, added to Select List at Stifel

Stifel analyst Paul Matteis initiated coverage of Neurocrine Biosciences with a Buy rating and $137 price target and added the stock to the firm's Select List. He sees Ingrezza in Tardive Dyskineisa having "blockbuster potential" and believes the drug has "a reasonable shot at succeeding" and expanding its market in Tourette's Syndrome. He also estimates cash flows from Elagolix could be worth close to $2B, Matteis tells investors.

  • 30

    Aug

  • 31

    Aug

NBIX Neurocrine
$115.86

-0.32 (-0.28%)

07/30/18
JEFF
07/30/18
NO CHANGE
Target $124
JEFF
Buy
Neurocrine price target raised to $124 from $105 at Jefferies
Jefferies analyst Biren Amin raised his price target for Neurocrine Biosciences to $124 after updating his market models for Orilissa and Ingrezza. The analyst arrives at Orilissa peak sales of $3B-plus given the launch price and expected uptake. He believes FDA approval in endometriosis provides "significant royalties" for Neurocrine. However, his latest quarterly survey suggests a flattening of Ingrezza market share in tardive dyskinesia. He now estimates Q2 Ingrezza sales of $83M, below the consensus of $84.3M. Amin keeps a Buy rating on Neurocrine.
08/01/18
LEHM
08/01/18
NO CHANGE
Target $135
LEHM
Overweight
Neurocrine price target raised to $135 from $100 at Barclays
Barclays analyst Geoff Meacham raised his price target for Neurocrine Biosciences to $135 following the company's Q2 results. Commercial execution continues to impress ahead of 2018 and 2019 catalysts, Meacham tells investors in a research note. He believes Neurocrine reported "another impressive quarter" for Ingrezza and keeps an Overweight rating on the shares.
08/01/18
HCWC
08/01/18
NO CHANGE
Target $162
HCWC
Buy
Neurocrine price target raised to $162 from $139 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised his price target for Neurocrine Biosciences to $162 saying the company "reported another strong quarter." The analyst views the 34% quarter-over-quarter increase of prescriptions a "strong indication" of Ingrezza's traction in the market and a reflection of "healthy commercial dynamics." Fein sees "momentum on multiple fronts" and reiterates a Buy rating on Neurocrine.
08/01/18
JEFF
08/01/18
NO CHANGE
Target $131
JEFF
Buy
Neurocrine price target raised to $131 from $124 at Jefferies
Jefferies analyst Biren Amin raised his price target for Neurocrine Biosciences to $131 saying Ingrezza posted a "strong beat" in Q2. Further, the analyst sees "several catalysts" before year-end. A "strong" Orilissa launch could lift shares and management reiterated that the Phase IIb T-Force GOLD study in Tourette's is on track for topline data by the end of 2018, Amin tells investors in a research note. He keeps a Buy rating on Neurocrine.

TODAY'S FREE FLY STORIES

PSNL

Personalis

$0.00

(0.00%)

10:59
06/20/19
06/20
10:59
06/20/19
10:59
Syndicate
Personalis indicated to open at $28, IPO priced at $17 »

Personalis (PSNL) priced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

AGCO

Agco

$75.20

0.33 (0.44%)

10:57
06/20/19
06/20
10:57
06/20/19
10:57
Conference/Events
Agco management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 24

    Jun

  • 25

    Jun

  • 26

    Jun

WORK

Slack Technologies

$0.00

(0.00%)

10:54
06/20/19
06/20
10:54
06/20/19
10:54
Syndicate
Breaking Syndicate news story on Slack Technologies »

Slack Technologies direct…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

VanEck Vectors Gold Miners ETF

$24.79

0.82 (3.42%)

10:50
06/20/19
06/20
10:50
06/20/19
10:50
Options
Recent call buyer in Gold Miners ETF hit the mother lode on Fed stance »

Recent call buyer in Gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMC

AMC Entertainment

$11.13

-0.39 (-3.39%)

10:45
06/20/19
06/20
10:45
06/20/19
10:45
Options
AMC Entertainment call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

10:45
06/20/19
06/20
10:45
06/20/19
10:45
General news
Breaking General news story  »

3-Month Bill Announcement…

10:45
06/20/19
06/20
10:45
06/20/19
10:45
General news
Breaking General news story  »

6-Month Bill Announcement…

TSN

Tyson Foods

$77.87

0.1 (0.13%)

10:45
06/20/19
06/20
10:45
06/20/19
10:45
Earnings
Tyson Foods sees adjusted EPS growth in 'high single digits' »

In analyst day slides,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

AAPL

Apple

$198.90

1.03 (0.52%)

10:44
06/20/19
06/20
10:44
06/20/19
10:44
Hot Stocks
Apple, in letter to Lighthizer, urges U.S. not to impose additional tariffs »

Apple said in a letter to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBLU

JetBlue

$19.16

0.11 (0.58%)

, EADSY

Airbus

$0.00

(0.00%)

10:43
06/20/19
06/20
10:43
06/20/19
10:43
Periodicals
JetBlue to order 13 A321XLR aircraft from Airbus, Reuters says »

JetBlue (JBLU) will order…

JBLU

JetBlue

$19.16

0.11 (0.58%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCEL

Atreca

$0.00

(0.00%)

10:40
06/20/19
06/20
10:40
06/20/19
10:40
Syndicate
Breaking Syndicate news story on Atreca »

Atreca opens at $19.90,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

DPUKY

Domino's Pizza Group

$0.00

(0.00%)

10:38
06/20/19
06/20
10:38
06/20/19
10:38
Periodicals
Domino's Pizza Group in talks to replace CEO, Sky News reports »

Domino's Pizza Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$160.99

-1.56 (-0.96%)

10:35
06/20/19
06/20
10:35
06/20/19
10:35
Options
Wayfair put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANIP

ANI Pharmaceuticals

$76.25

1.86 (2.50%)

10:33
06/20/19
06/20
10:33
06/20/19
10:33
Hot Stocks
ANI Pharmaceuticals announces FDA approval for Vancomycin supplement »

ANI Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACRS

Aclaris Therapeutics

$5.25

0.14 (2.74%)

10:31
06/20/19
06/20
10:31
06/20/19
10:31
Hot Stocks
FDA says Aclaris ad makes false or misleading claims about Eskata »

The FDA sent a letter to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:30
06/20/19
06/20
10:30
06/20/19
10:30
General news
EIA natural gas storage change for week ending June 14 »

Gas inventories 115 Bcf…

10:30
06/20/19
06/20
10:30
06/20/19
10:30
General news
Treasury Action: Treasuries remain richer on the day »

Treasury Action:…

GO

Grocery Outlet

$0.00

(0.00%)

10:28
06/20/19
06/20
10:28
06/20/19
10:28
Syndicate
Grocery Outlet indicated to open at $30, IPO priced at $22 »

Grocery Outlet (GO)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

10:27
06/20/19
06/20
10:27
06/20/19
10:27
General news
Trump tweets 'Iran made a very big mistake' »

President Trump tweeted,…

BCEL

Atreca

$0.00

(0.00%)

10:25
06/20/19
06/20
10:25
06/20/19
10:25
Syndicate
Atreca indicated to open at $20.30, IPO priced at $17.00 »

Atreca (BCEL) priced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

10:25
06/20/19
06/20
10:25
06/20/19
10:25
Conference/Events
Jefferies technology analysts to hold an analyst/industry conference call »

Analysts, along with Alan…

CVS

CVS Health

$53.97

-0.92 (-1.68%)

10:25
06/20/19
06/20
10:25
06/20/19
10:25
Conference/Events
CVS Health participates in a conference call with Morgan Stanley »

Healthcare Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

VSTM

Verastem

$1.72

-0.18 (-9.47%)

10:21
06/20/19
06/20
10:21
06/20/19
10:21
Downgrade
Verastem rating change at BTIG »

Verastem downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WORK

Slack Technologies

$0.00

(0.00%)

10:20
06/20/19
06/20
10:20
06/20/19
10:20
Syndicate
Slack Technologies direct listing indicated to open at $30-$34 per share »

Slack Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Shares

$130.24

2.35 (1.84%)

10:20
06/20/19
06/20
10:20
06/20/19
10:20
Options
Gold ETF option volume 7x normal as spot jumps 2% »

Gold ETF option volume 7x…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.